Analysis of Differential Gene Expression Profiles in Patients With Defined Ocular Inflammatory Diseases Using CDNA Microarrays and Proteomics
Sponsor study identifier
Secondary identifiers
observational
60
1 country
1
Study Start
February 1, 2002
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
October 24, 2007
Date type not reportedThis date has not been verified as actual or estimated.
This study will examine blood cells and other tissue samples from people with uveitis (eye inflammation) to try to gain a better understanding of this condition. It will look at 1) the differences in cells when uveitis is active and when it is under control; 2) the genes that control the functions of these cells during different stages of the condition; and 3) the proteins the cells make at these different stages. Patients 6 years of age or older with an eye inflammation of at least 8 weeks' duration may be eligible for this study. They must currently be enrolled in another NEI protocol for evaluation or treatment of uveitis. Participants will provide blood and possibly eye tissue samples as follows: Blood samples: Blood samples will be drawn, probably from an arm vein, during periods when the inflammation is bad and when it is quiet. No more than 60 mL (about 4 tablespoons) will be drawn at any visit, and no more than eight samples will be collected in 1 year. Tissue samples: For patients who require eye surgery, a sample of tissue or fluid that is removed as a routine part of surgery may be provided to investigators in this study for research purposes. Samples will be collected during patients' visits scheduled as part of their other protocol. The samples will be labeled with a special code number to preserve the patient's identity.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 24, 2007
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1, 2002
Date type not reportedThis date has not been verified as actual or estimated.
July 26, 2006
Actual (reported)July 27, 2006
Actual (reported)October 24, 2007
Date type not reportedThis date has not been verified as actual or estimated.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995 Oct 20;270(5235):467-70. doi: 10.1126/science.270.5235.467.
First Submitted
July 26, 2006
First Posted
July 27, 2006
Study Start
February 1, 2002
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
October 24, 2007
Date type not reportedThis date has not been verified as actual or estimated.
Daclizumab and Sirolimus to Treat Uveitis
Contact the study team to confirm eligibility.
Last Updated
July 2, 2017
Record last verified: 2007-10-24
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: